


Tulosyksikkö/tulosalue: Syöpäkeskus Yht. 139

Päiväys: 30.4.2021

Tutkimuksen nimi	Vastuuhenkilö	Kuvaus
Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back: a multicentre clinical pilot study	Mattson Johanna	
A phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride	Mattson Johanna	
Suorien antikoagulanttien la- boratoriomonitorointi eteis- värinäpotilailla	Lassila Riitta	
Palliative care and End-of-life care of cancer patients – na- tional investigation	Saarto Tiina	
A Phase 1, open-label, first-in-human, multi-center, study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2315497 Injection, in patients with metastatic castration	Vaalavirta Leila	
A phase 3, interventional, douple-blind, placebo-controlled study to assess the safety and efficacy of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have received treatment with prior anticancer therapies	Jaakkola Panu	
An Open-label, Randomized Phase 3 Study of MK-6482 Ver- sus Everolimus in Participants with Advanced Renal Cell Carci-	Peltola Katriina Johanna	



noma That Has Progressed Af- ter Prior PD-1/L1 and VEGF- Targeted Therapies		
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group	Hernberg Micaela Maria	
Prolonged sick leave among breast cancer patients in the capital area of Finland	Poikonen-Saksela Paula	
Outcome of preoperative and definitive chemoradiotherapy in patients with NSCLC treated in HUCH	Anttonen Anu	
TYH2018306 Inducing systemic antitumor effects with local on- colytic adenovirus treatment	Hemminki Akseli	
The safety of an modified electron applicator in radiotherapy of superficial basal cell carcinomas	Anttonen Anu	
Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome	Porkka Kimmo	
A Phase 3, Randomized, Openlabel, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome—Positive Acute Lymphoblastic Leukemia (Ph+ A-	Porkka Kimmo	
European Treatment and Outcome Study - UTOS - for CML	Mustjoki Satu	





Acquired hemophilia A in the Nordic countries	Lehtinen Anna-Elina	
A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With Eculizum	Lehtinen Anna-Elina	
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma	Leppä Sirpa	
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemo- therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (GCT3013-05)	Leppä Sirpa	
Developing melanoma diagnosis and prognosis with artificial in- telligence	Tulokas Sanni Katja Aliisa	
A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced	Karihtala Peeter	



Impact of COVID-19 infections on cancer patients: prospective, observational multicenter study	Karihtala Peeter	
Molecular profiling to optimize lymphoma therapies (TYH2019269)	Leppä Sirpa	
Optimal therapy for malignant lymphomas (TYH2021321)	Leppä Sirpa	
Open-label, non-randomized Phase 1, multicenter study to as- sess radium-223 biodistribution in participants with bone meta- static castration resistant pros- tate cancer (CRPC) receiv- ingradium-223 dichloride treat- ment	Peltola Katriina	
Metabolic vulnerabilities for personalized therapeutic ap- proaches in acute myeloid leu- kemia	Kontro Mika	
Functional genomic approaches and novel biomark to enhance cancer immunology (TYH2019236)	Mustjoki Satu	
Cultural sensitive nursing care of multicultural cancer patient- patients, family members and professionals point of view	Repo Pirjo Marita	
SCAN ALL – Study of Nordic CML and ALL Patients using Next Generation Sequencing Analysis for Low Level Muta- tions	Porkka Kimmo Veli Kristian	
AXSANA (AXillary Surgery After NeoAdjuvant Treatment)	Niinikoski Laura Anna-Liisa	
Novel Diagnostical and Thera- peutical Targets in Multidisci- plinary Coagulation Disorders Services	Lassila Riitta	



Open-label, non-randomized Phase 1, multicenter study to as- sess radium-223 biodistribution in participants with bone meta- static castration resistant pros- tate cancer (CRPC) receiv- ingradium-223 dichloride treat- ment	Peltola Katriina Johanna	
A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia	Keränen Mikko Antti Ilmari	
Patient reported outcomes in lymphoma patients during treatment and follow-up	Leppä Sirpa	
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODI- FIED T-CELLS	Leppä Sirpa	
A Phase 1/2 Multicenter, Openlabel Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma	Anttila Pekka Matias	
A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients with Injectable Solid Tumors	Peltola Katriina Johanna	
Evaluation of the enhanced ra- diotherapy treatment planning system	Vaalavirta Leila Anita	
Phase 1/2a First-In-Human Study of BMS-986218 Monoclo- nal Antibody Alone and in Com-	Hernberg Micaela Maria	




bination with Nivolumab in Advanced Solid Tumors (CA022-001)		
Prostate brachytherapy: long- term oncological and functional outcomes	Visapää Harri	
An observational study of blina- tumomab safety, effectiveness, utilisation and treatment prac- tices.	Wartiovaara-Kautto Ulla	
Patient preferences for multiple myeloma treatment: A qualita- tive study to investigate which treatment characteristics multi- ple myeloma patients find most important	Silvennoinen Raija	
A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 "The FUZE Clinical Trial"	Peltola Katriina Johanna	
A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinom	Peltola Katriina	
A Phase 1, open-label, first-in- human, multi-center, study to evaluate the safety, tolerability, pharmacokinetics, and anti-tu- mor activity of a thorium-227 labeled antibody-chelator con- jugate, BAY 2315497 Injection, in patients with metastatic cas- tration r	Peltola Katriina	
Adjuvant therapy of melanoma: treatment experiences in HUCH Comprehensive Cancer Center between 2018 and 2020	Mäkelä Siru	



Efficacy and safety of immuno- oncological treatment of mela- noma in HUH Comprehensive cancer center between 2017 and 2020	Mäkelä Siru	
"Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back: a multicentre clinical pilot study".	Mattson Johanna	
A phase I/Ib open-label, multicenter dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)	Leppä Sirpa	
A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocyti	Kontro Mika	
The effect of seasonal prophylactic influenza vaccination and factors influencing the patients' immune-competence during anti-PD-1 treatment of patients with melanoma	Hernberg Micaela	
"A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors"	Hernberg Micaela	
Outcome of preoperative and definitive chemotherapy fin pa- tients with oesophageal carci- noma treated in HUS Cancer Center, 2008-2018	Anttonen Anu	
Ablative STEreotactic RadiO- therapy wIth Durvalumab	Anttonen Anu	




(MEDI4736). An open label ran-		
domized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patients with T1-2NoMo Nonsmall Cell Lung Cancer (NSCLC)		
PLANNING AND IMPLEMENTATION OF PALLIATIVE RADIOTHERAPY OF BONE METASTASES BASED ON DIAGNOSTIC CT SCAN INSTEAD OF DOSE PLANNING CT SCAN	Anttonen Anu	
Gene therapy of ovarian cancer and head and neck cancer	Hemminki Akseli	
A Randomized, Open-label, Phase 3 Study Comparing Once- weekly vs Twice-weekly Carfil- zomib in Combination with Le- nalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)	Anttila Pekka	
A real-world study of the outcomes of atezolizumab (PD-L1 antibody) combined with nabpaclitaxel (Abraxane) in the first line treatment of women with locally advanced or metastatic triple-negative breast cancer whose tumors are PD-L1 positive	Ahola Tytti	
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	Hervonen Juhana	
R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma,	Leppä Sirpa	






=80 years, or frail =75 years – an open label randomized Nor- dic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BE		
Real world evidence (RWE) study of Ra-223-dichloride in Finland in pre-dominantly bone-metastatic castration resistant prostate cancer between 2014-2019.	Utriainen Tapio	
Development of SSEA4-targeted CAR T-cells for treatment of solid tumors	Leppä Sirpa	
Venetoclax, lenalidomide and rituximab in patients with re- lapsed / refractory mantle cell lymphoma (VALERIA)	Pasanen Annika Hanna Kristi- ina	
AN INTERNATIONAL, MULTI- CENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINA- TION REGIMENS OF IMMU- NOTHERAPY WITH ALLOGE- NEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WITH ACUTE MYELOID LEUKAE- MIA THAT ARE IN REMIS- SION WITH PERSIST	Porkka Kimmo	
Gene therapy of ovarian cancer and head and neck cancer	Hemminki Akseli Eetu	
Treatment Protocol for Children (1.0 - 17.9 years of age) and young adults (18-45 years of age) with Acute Lymphoblastic Leukemia	Wartiovaara-Kautto Ulla	
Impact of COVID-19 infections on cancer patients: prospective, observational multicenter study	Leppä Sirpa	
A phase 3, multicenter, open-label, randomized study with gilteritinib or midostaurine in combination with induction and	Kontro Mika	






consolidation chemotherapy followed by 1 year of maintenance treatment in patients with newly diagnosed acute myeloid leukaemia (AML) o		
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cispl	Peltola Katriina Johanna	
A Randomized, Multicenter, Double-blind, Placebo-con- trolled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Re- ceptor-Positive (ER+), Human Epidermal	Mattson Johanna	
Lutetium-177 PSMA -treatment for castration resistant prostate cancer	Vaalavirta Leila Anita	
APPLICATION OF MOLECU- LAR MEDICINE TO IMPROVE OUTCOME IN MYELODYS- PLASTIC SYNDROME PA- TIENTS WITH SENSITIVE DI- AGNOSTICS AND PERSONAL- IZED POST-TREATMENT MONITORING	Ebeling Freja	
Patient involvement in clinical pathway development, evaluation and improvement	Mattson Johanna	
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and	Hernberg Micaela	





nivoluMAb clinical Trial Evaluation 76K)		
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia o	Kontro Mika	
An open label, phase Ib, dose- escalation study evaluating the safety and tolerability of xen- tuzumab and ademaciclib in pa- tients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or	Utriainen Meri	
HUS-tietoaltaan hyödyntäminen hematologisten potilaiden diagnostiikan, hoidon valinnan ja seurannan mallitamisessa (eCare4Me blokki 2)	Koskenvesa Perttu	
TWO-STAGE, TWO-ARM, OPEN-LABEL PHASE II STUDY OF VENETOCLAX IN COMBINATION WITH AZA- CYTIDINE IN ACUTE MYE- LOID LEUKEMIA PATIENTS SELECTED USING EX VIVO DRUG SENSITIVITY SCREEN- ING.	Kontro Mika	
A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemo- therapy Alone as Second-Line Treatment in Patients with Pan- creatic Adenocarcinoma TRYbeCA-1 – TRial of erYaspase in pancreatic CAncer	Halonen Päivi	
Utilizing the HUS Data Lake in the modelling of the diagnostics, choice of treatment and follow	Koskenvesa Perttu	






up of patients with hematologic diseases (eCare4Me block 2)		
Prostate and breast cancer patients: health-related quality of life and effectiveness and costeffectiveness of treatment, jatkolupa	Roine Risto	
A Phase 1/2, Open-label Study of Nivolumab Monotherapy, Ipilimumab Monotherapy, or Nivolumab combined with Ipili- mumab in Subjects with Ad- vanced or Metastatic Solid Tu- mors. Protocol CA209032	Peltola Katriina	
External beam radiation therapy for differentiated thyroid cancer: treatment experiences and outcomes in Helsinki University Hospital between 2009 and 2018	Ahtiainen Veera	
A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2	Ahola Tytti	
A Phase 1/2a Study of BMS- 986205 Administered in Com- bination with Nivolumab (anti- PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Anti- body) in Advanced Malignant Tumors	Peltola Katriina	
Cultural sensitive nursing care of multicultural cancer patiest- patients, family members and professionals point of view	Repo Marita	
A randomized , douple-blind, controlled phase 3 study of	Peltola Katriina	



cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate or poor ris		
Idarutsimabi HUS-piirissä	Lassila Riitta	
Safety and efficacy of BNCT in treating head and neck cancer patients	Vaalavirta Leila Anita	
Prolonged sick leave among breast cancer patients in the capital area of Finland	Poikonen-Saksela Paula	
A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlu	Wartiovaara-Kautto Ulla	
SIde effects and prevention of side effects during cancer treat- ment, with special focus on im- munotherapy related autoim- mune toxity	Hernberg Micaela	
"Effect of educational nursing intervention on nutrition related chemotherapy induced side-effects' self-care activity among the patients with colorectal cancer"	Tuominen Leena	
"Taidetyöskentelyn vaikutus syöpäpotilaiden, heidän läheis- tensä ja sairaalan henkilökun- nan sairaalakokemukseen ja psyykkiseen hyvinvointiin"	Aalto-Viljakainen Tia	
A study of efficacy and safety of long-acting low dose ropeginter- feron in patients with chronic myeloid leukemia treated with	Koskenvesa Perttu	






	bosutinib from diagnosis: a randomized prospective trial		
•	Feasibility of switching fluoro- pyrimidine due to cardiotoxicity in patients with gastrointestinal cancer: A retrospective, interna- tional and non-interventional study	Halonen Päivi	
	BNCT-hoidon teho ja turvalli- suus pään ja kaulan alueen syö- päpotilailla	Vaalavirta Leila	
	Rintasyöpäpotilaiden pitkitty- neet sairauspoissaolot pääkau- punkiseudulla Suomessa	Poikonen-Saksela Paula	
•	Randomized,opel-label study of Rituximab/Ibrutinib vs Rituxi- mab/Chemotherapy in older pa- tients with untreated mantle cell lymphoma	Pasanen Annika	
•	A multi-center, cross-sectional, reprospective study to evaluate whether patients with Hemophilia B has a different phenotype compared to patients with Hemophilia A (B-NORD)	Lassila Riitta	
•	An open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2287411 Injection, in patients with solid tumors known to express mes	Vaalavirta Leila	
	A multicenter, open-label, phase I study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of RO7082859 as a single agent and in combination with obinutuzumab administered after a fixed, single dose pre-treatment of obinutuzumab	Leppä Sirpa	



A phase 3, multicenter, randomized, double-blind study to compare the efficacy and safety of oral Azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red bood cell transfusion-dependent anemia and thrombocytop	Ebeling Freja	
Mukautetun elektronikeilarajai- men käytön turvallisuus pinnal- listen tyvisolusyöpien sädehoi- dossa	Anttonen Anu	
An open-label, multi-center, ex- tension study for subjects who participated in prior guadecita- bine clinical studies	Porkka Kimmo	
A phase Ib, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in adults subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)	Porkka Kimmo	
Suomen hematologian rekisteri (SHR): väestöpohjainen seurantatutkimus kokskien veritautien ja perinnöllisten verenvuototautien ilmaantuvuutta, esiintyvyyttä, diagnostiikkaa, hoitoja ja hoitotuloksia Suomessa	Porkka Kimmo	
NN7415-4322/Normaalin hoito- käytännön non-interventio- eli havainnointitutkimus A- ja B- hemofilia sairastaville vasta-ai- nepositiivisille tai - negatiivisille tutkittaville	Lassila Riitta	
Novel biomarkers and drug targets for renal cell cancer" (TYH2019217), korjattu	Jaakkola Panu	
The outcome of multiple myeloma patients treated with allogeneic stem cell transplantation	Nihtinen Anne	






Individualized treatment and follow-up for patients with soft tissue sarcoma. Proliferation and digital image analysis. Lung low-dose CT; prospective controlled study" (TYH20192016)	Blomqvist Carl	
Clinical and pathological aspects of melanoma among children in Finland	Hernberg Micaela	
Safety and pharmacokinetics of ODM-209 in patients with metastatic castration-resistant prostate cancer or estrogen receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer	Utriainen Tapio	
Registration of the data of the patients treated with hematopoietic stem cell transplantation	Niittyvuopio Riitta	
Studies of moderate Hemophilia A and B in Sweden, Denmark, Iceland, Finland and Norway, The "MoHem" study	Lassila Riitta	
Treatment and prognostic factors in locally advanced and advanced melanoma	Hernberg Micaela	
Effect of intravenous nutrition on survival and recovery of capecitabine-induced severe en- teritis	Nevala Riikka	
6306pois/jatkot tiedostoon 3882//A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Mela- noma in Subjects who are at High Risk for Recurrence	Hernberg Micaela	
A phase 3, randomized, douple- blind study of adjuvant immu- notherapy with nivolumab ver- sus ibilimumab after complete	Hernberg Micaela	



resection of stage IIIB/C or stage IV melanoma in subjects who are at high risk for recur- rence		
The effect of seasonal prophylactic influenza vaccination and factors influencing the patients' immune-competence during anti-PD-1 treatment of patients with melanoma	Hernberg Micaela	
"Protocol SAKK 35/14 Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II	Hernberg Micaela	
Syöpäpotilaiden elämän loppu- vaiheen hoito ja hoitolinjapää- tökset	Saarto Tiina	
COMBI-APlus: Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyr	Mäkelä Siru	
24-month prospective, multicentre, noninterventional study to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A (A-SURE)	Lehtinen Anna-Elina	
A phase III, randomized, dou- ple-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patienst with early relapsing recurrent (inop-	Utriainen Meri	



erable locally advanced or meta- static) triple-negative breast cancer		
Rintasyövän molekylaariset ala- tyypit liitännäishoitona attenutn kabesitabiinin tehon arvioin- nissa	Joensuu Heikki	
Glioomien lisäsädehoito HYKS Syöpäkeskuksessa vuosina 2008-2017	Jääskeläinen Anna-Stina	
A randomized, douple-blind, phase 2/3 study of relatlimab combined with nivolumab versus nivolumab in participants with previously untreated metastatic or unresectable melanoma	Hernberg Micaela	
TRIANGLE. Autologous Trans- plantation after rituximab/Ibru- tinib/Ara-c containig induction generalized mantle cell lym- phoma- a randomized European mcl network trial	Leppä Sirpa	
Precision medicine in B-sell lymphomas	Leppä Sirpa	
A phase 2, single-arm, multi-co- hort, multi-center trial to deter- mine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell Non- Hodgkin lymphoma	Leppä Sirpa	
Paikallisen ja systeemisesti levinneen melanooman taudinkulku ja seuranta HYKS-sairaanhoitopiirissä 2008-2017	Hernberg Micaela	
A phase II, randomized, active- controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of un- known primary site who	Suonpää Pia	





A phase 1 multicenter, open-label study to assess the safety, pharmacokinetics and preliminary efficacy of CC-92480 in combination with dexamethasone in subject with repalsed and refractory multiple myeloma	Anttila Pekka	
Rintasyöpäpotilaiden resilienssin alustava mallintaminen BOUNCE-hankkeessa (WP4)	Poikonen-Saksela Paula	
Allogeenisen kantasolusiirron tulokset AML-ja MDS- poti- lailla; treosulfaanipohjaisen ja myeloablatiivisen esihoidon ver- tailu	Nihtinen Anne	<u>'</u>
A prospective multicenter, phase II trial of ibrutinib plus venetoclax in patienst with clearance > 30ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations	Lindström Vesa	
Välittömän rintarekonstruktion vaikutus sytostaattihoidon ajankohtaan	Huttunen Tuomas	
An open-label, multi-center, phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) inpatienst 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia who are eligible for "7+3" or "5+2" chemotherapy	Porkka Kimmo	